Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage
Allergy · 2026-02 · 81 (2) · 388-401
DOI: 10.1111/all.70032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Allergy, online erschienen am 30.08.2025. Verfasst von Eugenio De Corso und 29 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real‐life studies have been conducted on small patient cohorts for up to 1 year.
Methods
This ambispective, multicentric, 2‐year‐long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers.
Results
The study involved 926 patients. At 24 months, median nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino‐nasal Outcome Test‐22 (SNOT‐22), and olfaction improved from baseline (all p < 0.0001). Patients with NPS > 4, and/or SNOT‐22 > 30, and/or Sniffin’ Sticks Identification Test‐16 (SSIT‐16) < 12 at 12 months demonstrated improvements in these outcomes over the second year. Overall, 18.7% of patients extended the dupilumab interdose interval to every 4 weeks (q4w). Notably, 91.2% of patients were “good‐to‐excellent” responders based on EPOS/Euforea criteria. Given the absence of standardized definitions for disease control and remission, we proposed different sets of criteria reporting results from different scenarios. Remission analysis is clinically important as it helps define treatment success and long‐term therapeutic goals. Most adverse events were mild‐to‐moderate; 2.4% of patients discontinued treatment due to safety concerns.
Conclusions
This is the largest real‐life study evaluating dupilumab in CRSwNP over 2 years. Dupilumab showed sustained effectiveness, with progressive improvements across all clinical outcomes. Dupilumab tapering did not compromise outcomes; treatment continuation allowed meaningful clinical benefits in late responders. Two‐year rates of disease control and remission are clinically relevant, although standardized criteria to assess these outcomes are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
- Department of Head, Neck and Sensory Organs, Catholic University of the Sacred Heart, Rome, Italy.
- Otorhinolaryngology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo Hospital, Università Degli Studi di Milano, Milan, Italy.
- Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", ENT Section, University of Catania, Catania, Italy.
- ENT Unit, Bellaria Hospital, Azienda USL Bologna, Bologna, Italy.
- Otorhinolaryngology Head and Neck Surgery Department, IRCCS Arcispedale Santamaria Nuova, Reggio Emilia, Italy.
ORCID-Profile: Eugenio De Corso, Claudio Montuori, Carlotta Pipolo, Ignazio La Mantia, Ernesto Pasquini, Angelo Ghidini, Veronica Seccia, Giancarlo Ottaviano, Elena Cantone, Giulia Dané, Gian Luca Fadda, Fabio Pagella, Carlo Cavaliere, Francesco Bussu, Jacopo Galli
Zitieren
APA
De Corso, E., Montuori, C., Pipolo, C., La Mantia, I., Pasquini, E., Ghidini, A., Seccia, V., Ottaviano, G., Cantone, E., Dané, G., Garzaro, M., Fadda, G. L., Torretta, S., Anastasi, F., Canevari, F. R. M., Pagella, F., Lucidi, D., Cavaliere, C., Pagliuca, G., …, & DUPIREAL Italian Study Group (2026). Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage. Allergy, 81(2), 388-401. https://doi.org/10.1111/all.70032
Vancouver
De Corso E, Montuori C, Pipolo C, La Mantia I, Pasquini E, Ghidini A, et al. Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage. Allergy. 2026;81(2):388-401. doi:10.1111/all.70032
BibTeX
@article{DeCorso2026,
author = {De Corso, Eugenio and Montuori, Claudio and Pipolo, Carlotta and La Mantia, Ignazio and Pasquini, Ernesto and Ghidini, Angelo and Seccia, Veronica and Ottaviano, Giancarlo and Cantone, Elena and Dané, Giulia and Garzaro, Massimiliano and Fadda, Gian Luca and Torretta, Sara and Anastasi, Francesca and Canevari, Frank Rikki Mauritz and Pagella, Fabio and Lucidi, Daniela and Cavaliere, Carlo and Pagliuca, Giulio and Maffei, Marianna and Bussu, Francesco and Corbò, Marco and D Auria, Leandro Maria and De Maio, Gabriele and Loperfido, Antonella and Gallo, Stefania and D Agostino, Giuseppe and Giannarelli, Diana and Galli, Jacopo and DUPIREAL Italian Study Group, DUPIREAL Italian Study Group},
title = {Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage},
journal = {Allergy},
year = {2026},
volume = {81},
number = {2},
pages = {388--401},
doi = {10.1111/all.70032}
}
EUVIMED